A detailed history of Legal & General Group PLC transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 16,559 shares of GLUE stock, worth $128,166. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,559
Previous 16,559 -0.0%
Holding current value
$128,166
Previous $87,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.59 - $6.97 $2,714 - $5,269
756 Added 4.78%
16,559 $87,000
Q1 2024

May 14, 2024

SELL
$4.26 - $8.46 $18,594 - $36,927
-4,365 Reduced 21.64%
15,803 $111,000
Q4 2023

Feb 15, 2024

SELL
$2.5 - $5.93 $36,142 - $85,730
-14,457 Reduced 41.75%
20,168 $113,000
Q3 2023

Nov 14, 2023

BUY
$4.78 - $7.22 $30,921 - $46,706
6,469 Added 22.98%
34,625 $165,000
Q2 2023

Aug 14, 2023

BUY
$4.53 - $8.4 $90,314 - $167,470
19,937 Added 242.57%
28,156 $192,000
Q1 2023

May 15, 2023

BUY
$5.95 - $8.21 $4,646 - $6,412
781 Added 10.5%
8,219 $64,000
Q4 2022

Feb 14, 2023

BUY
$6.71 - $9.72 $2,576 - $3,732
384 Added 5.44%
7,438 $56,000
Q3 2022

Nov 14, 2022

BUY
$7.17 - $12.16 $932 - $1,580
130 Added 1.88%
7,054 $57,000
Q2 2022

Aug 22, 2022

BUY
$6.15 - $14.99 $11,875 - $28,945
1,931 Added 38.67%
6,924 $67,000
Q1 2022

May 16, 2022

BUY
$10.36 - $20.41 $17,363 - $34,207
1,676 Added 50.53%
4,993 $70,000
Q4 2021

Feb 14, 2022

BUY
$16.28 - $27.15 $36,385 - $60,680
2,235 Added 206.56%
3,317 $68,000
Q3 2021

Nov 15, 2021

SELL
$18.59 - $42.21 $35,655 - $80,958
-1,918 Reduced 63.93%
1,082 $24,000
Q2 2021

Aug 12, 2021

BUY
$18.86 - $22.7 $56,580 - $68,100
3,000 New
3,000 $69,000

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $362M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.